{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002458","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.301203+00:00","generated_at":"2026-05-15T06:04:26.142147+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B","bullets":["FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.","Imdusiran has achieved functional cure in 10 chronic HBV patients in clinical trials to date.","Fast Track may enable Accelerated Approval, Priority Review, or Rolling Review of a BLA or NDA.","CEO Lindsay Androski said designation validates imdusiran as an important drug candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002458","json":"https://secwatch.observer/filing/0001171843-26-002458.json","markdown":"https://secwatch.observer/filing/0001171843-26-002458.md","text":"https://secwatch.observer/filing/0001171843-26-002458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/0001171843-26-002458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/f8k_041426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:04:26.142147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}